PREEMPTIVE TREATMENT FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE
- 15 March 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 65 (5) , 747-752
Abstract
Background. Rapid quantifiable diagnostic techniques for the diagnosis of cytomegalovirus (CMV) infection may predict patients at risk of CMV pneumonitis and allow preemptive antiviral treatment. Methods. Using CMV antigenemia as a prospective surveillance technique for CMV infection, we compared the outcome of preemptive treatment (PT) with ganciclovir, 10 mg/kg/day for 21 days directed by “high levels” of CMV antigenemia (PT group, n=19), with the outcome in a group of historical controls (n=18) treated with ganciclovir when CMV illness occurred. Greater than 50 antigen-positive cells per 2×105 polymorphonuclear leukocytes was considered to be high-level antigenemia. Results. Nine of the 18 controls developed high-level CMV antigenemia at a median of 33 days (range: 13-65 days) and 5 of the 9 developed CMV disease. Ten of the 19 PT group had high levels of CMV antigenemia detected at a median of 47 days (range: 20-63 days) and were given ganciclovir; none developed CMV disease. There was a significantly lower incidence of CMV disease in the PT group in comparison to controls (0 of 19 vs. 5 of 18:P=0.019). Conclusion. We have reduced the incidence of CMV disease using preemptive treatment, and because of a 100% negative predictive value, we omitted unnecessary antiviral prophylaxis for many at-risk patients.Keywords
This publication has 15 references indexed in Scilit:
- Detection of human cytomegalovirus antigenaemia: a rapid diagnostic technique for predicting cytomegalovirus infection/pneumonitis in lung and heart transplant recipients.Thorax, 1995
- THE COST IMPACT OF CYTOMEGALOVIRUS DISEASE IN RENAL TRANSPLANT RECIPIENTSTransplantation, 1993
- Ganciclovir Prophylaxis for Cytomegalovirus Infections in Pulmonary Allograft RecipientsAmerican Review of Respiratory Disease, 1992
- A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease after Heart TransplantationNew England Journal of Medicine, 1992
- Monitoring of Human Cytomegalovirus Infections and Ganciclovir Treatment in Heart Transplant Recipients by Determination of Viremia, Antigenemia, and DNAemiaThe Journal of Infectious Diseases, 1991
- Management of cytomegalovirus antibody negative patients undergoing heart transplantation.Journal of Clinical Pathology, 1990
- Cytomegalovirus, varicella-zoster virus, and Coxsackie B virus-specific IgM antibody responses in children with cancerSerodiagnosis and Immunotherapy in Infectious Disease, 1990
- Progressive Disease Due to Ganciclovir-Resistant Cytomegalovirus in Immunocompromised PatientsNew England Journal of Medicine, 1989
- Effect of centrifugal enhancement of infectivity on the rapid detection of human cytomegalovirus in cell culture by immunofluorescence using a monoclonal antibody to an immediate early nuclear antigenSerodiagnosis and Immunotherapy in Infectious Disease, 1987
- Predictive Value of a Single Diagnostic Test in Unselected PopulationsNew England Journal of Medicine, 1966